Go to Page # Page of 11
loading

Influenza Therapeutic Developments By Kimberly Armstrong

 Kimberly Armstrong
  13th-Dec-2018
Description: Kimberly Armstrong a branch chief explaining the Influenza Therapeutics. Influenza Antivirals as of September 2018 and comparing it with a current portfolio focused on direct-acting antivirals. Studies on the patients less emphasis.
Views: 3605
Domain: Medical
Category: Biology
Contents:
Influenza Therapeutics
Kimberly Armstrong, PhD, MT(ASCP)
Branch Chief (Acting), Therapeutics
October 29, 2018
October 29-30, 2018 | Grand Hyatt • Washington, D.C.

Influenza Antivirals as of September 2018

Adamantanes:
M2 blockers

Neuraminidase
inhibitors

-Rimantadine
-Amantadine

-Oseltamivir
-Zanamivir
-Peramivir

Stiver 2003 CMAJ 168:49

Saving Lives. Protecting Americans.

2

Current ... See more

Recent Presentations

...
19 April, 2019

FDA Approach to the Opioids Crisis

Opioid Crisis is not one crisis, but multiple challenges to prescribers, patients & healthcare system. FDA is working in a prioritized way in multiple areas to confront opioid over

...
18 April, 2019
Ralph F. Hall
17 April, 2019